In conclusion, the implementation of a Patient Navigation Program at our tertiary cancer center in Egypt significantly reduced treatment delays for HER2-positive early breast cancer, particularly by shortening the critical interval between MOH approval and initiation of dual anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.